Cargando…
Prevention of Hepatocellular Carcinoma Development Associated with Chronic Hepatitis by Anti-Fas Ligand Antibody Therapy
A persistent immune response to hepatitis viruses is a well-recognized risk factor for hepatocellular carcinoma. However, the molecular and cellular basis for the procarcinogenic potential of the immune response is not well defined. Here, using a unique animal model of chronic hepatitis that induces...
Autores principales: | Nakamoto, Yasunari, Kaneko, Shuichi, Fan, Hong, Momoi, Takashi, Tsutsui, Hiroko, Nakanishi, Kenji, Kobayashi, Kenichi, Suda, Takashi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194047/ https://www.ncbi.nlm.nih.gov/pubmed/12391022 http://dx.doi.org/10.1084/jem.20020633 |
Ejemplares similares
-
Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing
por: Suda, Takashi, et al.
Publicado: (1997) -
Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages
por: Kiener, Peter A., et al.
Publicado: (1997) -
Identification of Amino Acid Residues Important for Ligand Binding to Fas
por: Starling, Gary C., et al.
Publicado: (1997) -
Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand
por: Suzuki, Ivy, et al.
Publicado: (1998) -
CD40 Activation Induces Apoptosis in Cultured Human Hepatocytes via Induction of Cell Surface Fas Ligand Expression and Amplifies Fas-mediated Hepatocyte Death during Allograft Rejection
por: Afford, Simon C., et al.
Publicado: (1999)